瑞普生物(300119) - 2025 Q2 - 季度业绩预告

I. Current Period Performance Forecast This section outlines the company's estimated financial performance for the first half of 2025, projecting significant growth in net profit 1. Forecast Period This performance forecast covers the semi-annual operating results from January 1, 2025, to June 30, 2025 - The performance forecast period is from January 1, 2025, to June 30, 2025[3] 2. Performance Forecast: Upward Trend The company anticipates substantial growth in net profit attributable to shareholders and net profit after non-recurring gains/losses for H1 2025 2025 Semi-Annual Performance Forecast | Item | Current Period (Estimated) | Prior Year Period (Restated) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of the Listed Company | Profit: RMB 244.16 million – RMB 276.72 million | Profit: RMB 162.7783 million | 50% – 70% | | Net Profit Attributable to Shareholders of the Listed Company After Non-Recurring Gains and Losses | Profit: RMB 181.75 million – RMB 209.72 million | Profit: RMB 139.8102 million | 30% – 50% | - Prior period financial indicators have been restated in the "2024 Annual Report" to reflect the impact of business combinations under common control[3] II. Communication with Accounting Firm This section clarifies the current audit status of the preliminary performance forecast data 1. Audit Status Explanation The performance forecast data represents preliminary calculations by the company's finance department and has not yet been audited by an accounting firm - The data related to this performance forecast is a preliminary calculation by the company's finance department and has not been audited by an accounting firm[4] III. Explanation of Performance Changes This section details the key factors driving the company's performance growth, including strategic initiatives and non-recurring items 1. Drivers of Operating Performance Growth The company achieved both volume and profit growth by driving technological innovation, focusing on high-potential new businesses, and implementing lean management - The company drives high-quality development through technological innovation, focusing on customer needs with "scenario-based disease research + systematic solutions" to lead industry technological progress[5][6] - Leveraging a full product line system, the company builds a model of "high-quality products + disease monitoring and early warning + standardized epidemic control solutions + management services," innovating strategic collaborations with large-scale farming enterprises to increase market share and key account penetration in the poultry and livestock animal health sectors[6] - Focusing on high-potential segments such as pet medical care and overseas markets, new businesses achieved substantial growth, accelerating overseas product registration, channel development, talent recruitment, and international brand building, thereby speeding up the implementation of its global expansion strategy[6] - Implementing a "value-driven core" full-chain closed-loop operational management system, with lean management as a key tool, the company reshapes its profitability model through lean cost reduction and value innovation, improving production efficiency and reducing costs to achieve both volume and profit growth[6] 2. Composition of Non-Recurring Gains and Losses Non-recurring gains and losses for H1 2025 primarily stem from fair value changes in non-current financial assets, wealth management products, investment income, and government subsidies - Non-recurring gains and losses in H1 2025 primarily include fair value changes from non-current financial assets and wealth management products, investment income, and government subsidies[6] 3. Strategic Outlook The company will continue its "product leadership, system refinement" strategy, building a technological moat with new quality productive forces for high-quality development - The company will adhere to the "product leadership, system refinement" strategic path, building a technological moat with new quality productive forces, pursuing high-quality development, and steadfastly moving towards the goal of becoming a world-class high-tech biological enterprise[7] - The ongoing deep adjustment in the animal health industry will continue to clear out excess capacity, with industry profitability centralizing towards leading players and the value chain continuously upgrading[7] IV. Risk Warning and Other Related Information This section provides a crucial warning regarding the preliminary nature of the performance forecast and advises investor caution 1. Risk Warning This performance forecast is a preliminary, unaudited estimate; investors should exercise caution, as final financial data will be based on the company's semi-annual report - This performance forecast is a preliminary calculation by the company's finance department and has not been audited by an accounting firm; specific financial data will be subject to the company's disclosed 2025 semi-annual report[8] - Investors are kindly requested to make prudent decisions and be aware of investment risks[8]